Milestone Influenza Publication by Elsevier Journal Vaccine
Supplement launched at successful Influenza Conference
Amsterdam, October 14, 2008 – Last month during an influenza conference organized by the European Scientific Working Group on influenza (ESWI), the Elsevier journal Vaccine released a supplement dedicated to influenza vaccines. This publication provides a comprehensive, state-of-the-art overview on influenza vaccines and was supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Influenza, commonly known as (the) Flu, continues to be a major cause of mortality, and vaccination remains the mainstay of efforts to prevent and control the disease. Flu spreads around the world in seasonal epidemics, killing millions of people in pandemic and hundreds of thousands in non-pandemic years.
In their editorial in the supplement, Marie Paule Kieny and Keiji Fukuda of the World Health Organization (WHO) specifically address the pandemic influenza vaccine challenge and stress: ”that an efficient response at the outset of an influenza pandemic will depend on the robust global surveillance systems implemented by the WHO’s Global Influenza Surveillance Network”.
The Vaccine supplement focuses entirely on new developments in the area of human influenza vaccines, by bringing together key experts from many of the relevant disciplines in this field. “It is a highly valuable and very timely publication and I am convinced that it will be well-read across the world” stated Co-Guest Editor Gregory Poland, from the Mayo Clinic College of Medicine in Rochester, USA.
The 3rd European Influenza Conference in Portugal was organized by ESWI and had a scientific program including every aspect of influenza prevention, control and treatment. Beyond the science, the conference also offered sessions and workshops for governmental representatives and opinion leaders in healthcare. ESWI President and Co-Guest Editor of the Vaccine supplement Ab Osterhaus, from the Erasmus Medical Centre in Rotterdam, the Netherlands, considered the meeting a great success and said: “Communication and cooperation between scientists, policy makers and healthcare professionals is key to significantly reducing the burden of influenza, and the conference facilitated that process perfectly”.
Notes to editors:
To receive a copy of Vaccine Volume 26, Supplement 4; Influenza Vaccines: Research, Development and Public Health challenges (Guest editors: A.D.M.E. Osterhaus and G.A. Poland), please contact the press office at firstname.lastname@example.org.
The European Scientific Working Group on Influenza (ESWI) brings together influenza experts of different disciplines from all over Europe, in the aim to combat the impact of epidemic and pandemic influenza. ESWI communicates with all influenza stakeholders and facilitates interactions among them. The organization of the European influenza conferences (ESWI conferences) is a crucial means to realize this ambition.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Floris de Hon
+31 (0) 20 485 2498